When we excluded the first 2 years of follow-up, and further adjusted for lipid-lowering medication, PRS, FADS1/2 genotype, or the remaining plasma fatty acids, the observed associations of specific fatty acids with incident HCC and CLD mortality remained unchanged (Supplementary Tables 12, 13). This evidence concerns the gene FADS1 and congenital secretory chloride diarrhea 1.